Browsing Tag
psychiatry
2 posts
FDA gives CAPLYTA the go-ahead for major depressive disorder, boosting hopes for better remission rates
Find out how CAPLYTA’s FDA approval for major depressive disorder could redefine depression treatment and improve remission outcomes.
AbbVie’s $1.2bn bet on Gilgamesh’s bretisilocin signals a bold push into next-generation antidepressants
AbbVie to acquire Gilgamesh’s bretisilocin for up to $1.2B to expand its psychiatry pipeline. Find out how this short-acting psychedelic could reshape MDD care.